This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cynosure Receives Health Canada Authorization To Market PicoSure™, The First Picosecond Laser To Remove Tattoos And Benign Pigmented Lesions

WESTFORD, Mass., July 29, 2013 /PRNewswire/ --  Cynosure, Inc. (Nasdaq: CYNO), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced that it has received a medical device license issued by Health Canada for the Company's PicoSure Picosecond Laser Workstation. Cynosure plans to begin selling PicoSure through its North American direct sales force immediately.

PicoSure is the world's first picosecond laser indicated for the removal of tattoos and benign pigmented lesions. The device received 510(k) clearance from the U.S. Food and Drug Administration at the end of 2012 and was launched in the first quarter of 2013. PicoSure received CE Mark certification in Q1 2013, and is currently being marketed in the European Union.

"Health Canada's authorization of PicoSure supports our long-term growth strategy and broadens our presence internationally," said Michael Davin, Cynosure's Chairman and Chief Executive Officer. "Following a successful launch in both the U.S. and Europe, demand for PicoSure continues to achieve our expectations. This additional clearance generates a first-mover advantage for Cynosure in another key market." 

About Cynosure, Inc. Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical professionals to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, treat toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 100 other countries. For corporate or product information, visit Cynosure's website at www.cynosure.com

Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Cynosure, Inc., as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including market acceptance of PicoSure in Canada, levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, competition in the aesthetic laser industry, general business and economic conditions and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and subsequently filed quarterly report on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.                                                                                               

Contact: Scott SolomonVice PresidentSharon Merrill Associates, Inc.617.542.5300 cyno@investorrelations.com

 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,511.04 -87.16 -0.50%
S&P 500 2,091.41 -6.63 -0.32%
NASDAQ 5,098.9920 -16.39 -0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs